For the year ending 2025-12-31, ARCT had -$61,119K decrease in cash & cash equivalents over the period. -$74,501K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenue | 82,031 |
| Total research and development | 112,212 |
| General and administrative | 46,079 |
| Other | -10,477 |
| Net loss | -65,783 |
| Depreciation and amortization | 3,025 |
| Share-based compensation expense | 25,408 |
| Foreign currency transaction loss | -382 |
| Impairment of right-of-use assets | 1,897 |
| Accounts receivable | 1,590 |
| Prepaid expenses and other current assets | -5,004 |
| Right-of-use assets | -3,696 |
| Accounts payable | -2,959 |
| Accrued liabilities | -15,265 |
| Deferred revenue | -23,872 |
| Lease liabilities | -4,214 |
| Net cash used in operating activities | -74,271 |
| Acquisition of property and equipment | 230 |
| Net cash used in investing activities | -230 |
| Proceeds from debt | 15,000 |
| Proceeds from exercise of stock options | 1,109 |
| Proceeds from issuance of common stock under equity plans | 585 |
| Proceeds from issuance of common stock, net of issuance costs | 11,688 |
| Payments on debt obligations | 15,000 |
| Net cash provided by (used in) financing activities | 13,382 |
| Net decrease in cash, cash equivalents and restricted cash | -61,119 |
| Cash, cash equivalents and restricted cash, beginning of year | 293,913 |
| Cash, cash equivalents and restricted cash, end of year | 232,794 |
Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. (ARCT)